Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
Epcoritamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Fazpilodemab is a Chimeric Humanized Monoclonal antibody targeting FLT2, expressed in Mammalian cells.
Enibarcimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ADM, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Retifanlimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Retifanlimab (INCMGA-0012) is an anti-PD-1 monoclonal antibody. INCMGA0012 is currently in the clinical proof-of-concept (PoC) stage. At the same time, Incyte is exploring the efficacy of INCMGA0012 monotherapy in high satellite unstable endometrial cancer and Merkel cell carcinoma.
Dostarlimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody jointly developed by TESARO and AnaptysBio. It binds to the PD-1 receptor with high affinity, thereby blocking its binding to PD-L1 and PD-L2 ligands.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Tarcocimab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
Aducanumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting APP Abeta, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Aducanumab has been used in trials studying the treatment of Alzheimer's Disease.
Volagidemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting GCGR, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Pascolizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL4, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Pascolizumab is a humanized anti-IL-4 monoclonal antibody that can inhibit upstream and downstream events associated with asthma, including (T(H)2) cell activation and immunoglobulin E production.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Reozalimab is a Human Monoclonal antibody targeting B7-H1, expressed in Mammalian cells.
Host
CHO cells
Reactivity
Human
Applications
Conjugation
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.